Pfizer Plans to Launch Remicade Biosimilar in November
October 17 2016 - 06:06PM
Dow Jones News
By Tess Stynes
Pfizer Inc. plans to start U.S. shipments of biosimilar
Inflectra, its copycat version of Johnson & Johnson's
anti-inflammatory drug Remicade, at a 15% discount to Remicade's
wholesale prices starting in late November.
Pfizer, which has U.S. commercialization rights to Inflectra,
said the estimated wholesale price doesn't include discounts to
payers, distributors and others.
Inflectra, developed by South Korea pharmaceutical company
Celltrion Inc., received Food and Drug Administration approval
earlier this year but faced legal challenges over a patent for
Remicade.
Inflectra, the second approved biosimilar treatment in the U.S.,
is approved to treat rheumatoid arthritis, ulcerative colitis and
Crohn's disease.
Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
October 17, 2016 17:51 ET (21:51 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024